| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
139,229 |
182,993 |
316,353 |
594,697 |
| Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$56,737,885 |
| Total People Sold |
5 |
5 |
6 |
7 |
| Total Sell Transactions |
11 |
15 |
24 |
53 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2022-10-14 |
4 |
AS |
$89.89 |
$359,560 |
D/D |
(4,000) |
324,324 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2022-08-15 |
4 |
AS |
$95.21 |
$285,630 |
D/D |
(3,000) |
328,324 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2022-08-12 |
4 |
AS |
$94.75 |
$379,000 |
D/D |
(4,000) |
331,324 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2022-08-11 |
4 |
AS |
$95.62 |
$286,860 |
D/D |
(3,000) |
44,088 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2022-08-09 |
4 |
S |
$95.93 |
$4,914,664 |
D/D |
(51,216) |
55,251 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2022-08-09 |
4 |
OE |
$67.81 |
$3,222,738 |
D/D |
47,526 |
102,777 |
|
- |
|
| Guyer Charles Greg |
EVP, Chief Technical Officer |
• – – |
2022-08-08 |
4 |
S |
$96.56 |
$599,155 |
D/D |
(6,205) |
42,168 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2022-08-05 |
4 |
AS |
$94.50 |
$330,750 |
D/D |
(3,500) |
30,726 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2022-08-05 |
4 |
OE |
$67.81 |
$237,335 |
D/D |
3,500 |
34,226 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2022-07-08 |
4 |
AS |
$89.50 |
$656,662 |
D/D |
(7,337) |
30,726 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2022-07-08 |
4 |
AS |
$90.00 |
$665,820 |
D/D |
(7,398) |
58,941 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2022-06-29 |
4 |
D |
$83.92 |
$48,338 |
D/D |
(576) |
38,063 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2022-06-03 |
4 |
D |
$77.49 |
$544,057 |
D/D |
(7,021) |
47,088 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2022-05-26 |
4 |
AS |
$78.94 |
$103,254 |
D/D |
(1,308) |
54,109 |
|
- |
|
| Alles Mark J |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
7,280 |
|
- |
|
| Slamon Dennis |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
26,619 |
|
- |
|
| Ho Maykin |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
12,450 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
85,568 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
108,994 |
|
- |
|
| Anderson Elizabeth M |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
18,890 |
|
- |
|
| Dere Willard H |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
23,390 |
|
- |
|
| Hombach Robert J. |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
26,310 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
28,950 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,980 |
40,840 |
|
- |
|
| Burkhart Erin |
GVP, Chief Accounting Officer |
• – – |
2022-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
11,130 |
11,130 |
|
- |
|
2549 Records found
|
|
Page 7 of 102 |
|
|
1.44 (1.6%) 
